Clinical trial · Observational
Evaluation of Pregnancy Associated Plasma Protein A (PAPPA) as a Biomarker in Breast Cancer.
NCT06174571CI-TRIAL-00072358unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This work aims to: 1. Evaluation of the role of pregnancy associated plasma protein A( PAPPA ) in diagnosis \& early detection of breast cancer. 2. Evaluation of the relationship between ( PAPPA ) levels and stages of breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- patients diagnosed with breast cancer at different stages of the disease.
- label
- 2
- description
- apparently healthy females as a control group.
Primary outcomes (1)
- measure
- Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.
- timeFrame
- baseline
- description
- Quantitative measurement of pregnancy associated plasma protein A in female patients with breast cancer.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * female patients with breast cancer who were diagnosed by histopathological studies and did not receive any treatment. Exclusion Criteria: * Patients who received chemotherapy or radiotherapy. * Patients with known other organ malignancy.
References
Publications (0)
Data not yet available
No reference posted for this study.